1. Home
  2. YSG vs FBRX Comparison

YSG vs FBRX Comparison

Compare YSG & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YSG

Yatsen Holding Limited

HOLD

Current Price

$3.22

Market Cap

283.5M

ML Signal

HOLD

Logo Forte Biosciences Inc.

FBRX

Forte Biosciences Inc.

HOLD

Current Price

$31.43

Market Cap

487.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YSG
FBRX
Founded
2016
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.5M
487.2M
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
YSG
FBRX
Price
$3.22
$31.43
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$67.00
AVG Volume (30 Days)
144.7K
384.5K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.30
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
$23.08
N/A
Revenue Next Year
$9.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.87
$4.91
52 Week High
$11.04
$35.80

Technical Indicators

Market Signals
Indicator
YSG
FBRX
Relative Strength Index (RSI) 45.30 58.01
Support Level $2.87 $26.67
Resistance Level $4.31 $31.71
Average True Range (ATR) 0.18 3.33
MACD 0.05 0.70
Stochastic Oscillator 86.67 65.23

Price Performance

Historical Comparison
YSG
FBRX

About YSG Yatsen Holding Limited

Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.

About FBRX Forte Biosciences Inc.

Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.

Share on Social Networks: